Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Divalpro 125 Sprinkles - Philippines FDA Drug Approval Details

Approvals/Philippines FDA/Divalpro 125 Sprinkles

Approved

STANDARD

Divalpro 125 Sprinkles

Cadila Healthcare Limited🇵🇭 Food and Drug Administration - Philippines

Approval Date: Jul 14, 2025
Approval ID: feb6ef2ccef81b4f
Company: Cadila Healthcare Limited
Type: Standard

Approval Details

Approval Id: feb6ef2ccef81b4f
Drug Approval Philippines Name: Divalpro 125 Sprinkles
Product Name: Divalpro 125 Sprinkles
Registration Number: DRP-10123
Brand Name: Divalpro 125 Sprinkles
Generic Name: Divalproex sodium (as valproic acid)
Dosage Form: Capsule
Dosage Strength: 125mg
Manufacturer: Cadila Healthcare Limited
Importer: Zydus Healthcare Philippines Inc.
Distributor: Zydus Healthcare Philippines Inc.
Company Detail Path: /organization/cadila-healthcare-ltd
Issuance Date: 28 July 2021
Expiry Date: 27 July 2026
Classification: Prescription Drug (RX)

Active Ingredients

Approved

Quick Info

Agency

Philippines FDA

Country

🇵🇭

Approval Date

Jul 14, 2025

Approval ID

feb6ef2ccef81b4f

Type

Standard

Back to Philippines FDA Approvals